William D. Turner
Corporate Officer/Principal chez VERA THERAPEUTICS, INC.
Profil
William D.
Turner is currently the Chief Development Officer at Vera Therapeutics, Inc. Prior to his current position, he held the role of Senior Director-Regulatory Affairs at MedImmune Vaccines, Inc. and Medimmune, Inc. He also served as the Vice President-Regulatory Affairs at Dynavax Technologies Corp.
from 2006 to 2009.
From 2020 to 2022, he was the Chief Regulatory & Technical Operations Officer at Sierra Oncology, Inc. Before that, he worked as the SVP-Technical Operations & Regulatory at Aimmune Therapeutics, Inc. from 2018 to 2020.
Mr. Turner completed his undergraduate degree at The California State University.
Postes actifs de William D. Turner
| Sociétés | Poste | Début |
|---|---|---|
| VERA THERAPEUTICS, INC. | Corporate Officer/Principal | 08/01/2023 |
Anciens postes connus de William D. Turner
| Sociétés | Poste | Fin |
|---|---|---|
| SIERRA ONCOLOGY, INC. | Directeur Technique/Scientifique/R&D | 01/07/2022 |
| AIMMUNE THERAPEUTICS, INC. | Corporate Officer/Principal | 01/04/2020 |
| Medimmune, Inc. | Conseiller Juridique Général | - |
MedImmune Vaccines, Inc.
 MedImmune Vaccines, Inc. BiotechnologyHealth Technology MedImmune Vaccines, Inc. develops, manufactures and markets live vaccines. Its developed vaccine is inhaled FluMist. The company was founded on April 15, 1992 and is headquartered in Mountain View, CA. | Conseiller Juridique Général | - |
| DYNAVAX TECHNOLOGIES CORPORATION | Conseiller Juridique Général | - |
Formation de William D. Turner
| The California State University | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| DYNAVAX TECHNOLOGIES CORPORATION | Health Technology |
| VERA THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 4 |
|---|---|
MedImmune Vaccines, Inc.
MedImmune Vaccines, Inc. BiotechnologyHealth Technology MedImmune Vaccines, Inc. develops, manufactures and markets live vaccines. Its developed vaccine is inhaled FluMist. The company was founded on April 15, 1992 and is headquartered in Mountain View, CA. | Health Technology |
Sierra Oncology, Inc.
 Sierra Oncology, Inc. BiotechnologyHealth Technology Sierra Oncology, Inc. was a clinical stage drug development company of therapeutics for the treatment of cancer. The firm focused on advanced targeted therapeutics for the treatment of patients with significant unmet medical needs in hematology and oncology. Its product Momelotinib, a selective and orally-bioavailable JAK1, JAK2 & ACVR1 inhibitor with a differentiated therapeutic profile in myelofibrosis encompassing robust constitutional symptom improvements. The company was founded in May 2003 and is headquartered in San Mateo, CA. | Health Technology |
Aimmune Therapeutics, Inc.
 Aimmune Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aimmune Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of desensitization treatments for peanut and other food allergies. Its portfolio includes the characterized oral desensitization immunotherapy system. The firm product include Palforzia, which is an oral immunotherapy indicated for the mitigation of allergic reactions, including anaphylaxis that may occur with accidental exposure to peanut. The company was founded on June 24, 2011 and is headquartered in Brisbane, CA. | Health Technology |
| Medimmune, Inc. | Health Technology |
